Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05936827
Other study ID # Sport Study
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date March 1, 2023
Est. completion date December 31, 2024

Study information

Verified date June 2023
Source Precordior Ltd
Contact Kristiina RESEARCH & QUALITY DIRECTOR, PhD
Phone 0445950891
Email kristiina.santalahti@precordior.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this study is to produce a solution to measure the cardiorespiratory fitness (CRF), which can be used by commercially available smartphones without extra equipment, add-ons and special know-how. This observational study with follow-up is to test the feasibility of a new non-invasive cardiac measurement method (gyrocardiography, GCG) in detecting hemodynamic parameters to measure exercise capacity and cardiorespiratory fitness in healthy subjects. The objective is to produce a solution which can be used to measure the exercise capacity and cardiorespiratory fitness (CRF) of the exercisers, keep-fit athletes and professional athletes using hemodynamic parameters such as: - Heart rate and Heart rate variability - Cardiac Strength profile - Systolic and diastolic phase - Breathing frequency - VO2max Participants are either athletes or non-athletic persons. The athletes will perform spiroergometry and non-athletic persons ergometry to measure the CRF expressed as VO2max. Following parameters will be measured during the (spiro)ergometry: - Maximum workload (W) - VO2max (ml/kg/min) - HRmax - Blood lactate - Respiratory exchange ratio RER (VO2/VCO2) The GCG measurements for acquiring the hemodynamic parameters are performed before and after the (spiro)ergometry using smartphone. During a 1- minute GCG measurement, the smart phone is placed on the chest in the middle of the sternum.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Age: 18-65 years - No diagnosed cardiovascular diseases (mild hypertension or hypercholesterolemia are still allowed) - No medication affecting heart rate (i.e. Beta blocker) - Signed informed consent Follow-up visit: - Belong to non-athletic group - Intention to change physical activity habits - Willing to participate to the follow-up visit Exclusion Criteria: - Not meeting inclusion criteria - Declined to participate - Resting RR before the ergometry > 180/110mmHg

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Ergometry
Maximal exercise test is performed on a cycle ergometer (Ergoline 800 s; VIASYS Healthcare, Germany). The test begins at a workload of 50 W, which is increased by 25 W (males) every 1 min or the test begins with 25 W which is increased by 25 W (females) every 1 min until exhaustion. The mean workload during the last 4 min of work is calculated and the VO2max is estimated according to the American College of Sports Medicine (American College of Sports Medicine. ACSM's guidelines for exercise testing and prescription. Sixth edition. Baltimore: Williams & Wilkins 2000:304). Blood lactate concentration is measured immediately and 1 min after exhaustion from capillary samples (Biosen C-Line Glucose and Lactate analyzer, EKFdiagnostic GmbH, Germany). (Pahkala et al. 2013.)
Ergospirometry
VO2max is measured using a stationary bicycle ergometer (Ergoline 800 s; VIASYS Healthcare, Germany. For males, the test starts with 100 W which is increased by 25 W every 1 min until volitional exhaustion. For females, the test starts with 50 W which is increased by 25 W every 1 min until volitional exhaustion. Ventilation and gas exchange (Vyntus CPX, Vyaire Medical Gmbh, Leibnizstrasse, Hoechberg, Germany) are measured during the test. Subject's blood lactate concentration is measured from capillary samples immediately and 1 min after exhaustion (Biosen C-Line Glucose and Lactate analyzer, EKF-diagnostic GmbH, Germany). The heart rate of the participants is followed continuously (CardioSoft GE, CardioSoft V6.51; GE Medical Systems Information Technologies, USA). (Heiskanen et al. 2021.)

Locations

Country Name City State
Finland Paavo Nurmi Center Turku

Sponsors (2)

Lead Sponsor Collaborator
Precordior Ltd Paavo Nurmi Centre

Country where clinical trial is conducted

Finland, 

Outcome

Type Measure Description Time frame Safety issue
Primary The maximum (max) rate (V) of oxygen (O2) your body is able to use during exercise. 4 minutes
Primary Gyrocardiography measurement Lasts 1 minute and is performed at least once at rest before the (spiro)ergometry. 1 minute
Primary Gyrocardiography measurement Lasts 1 minute and is performed 3 minutes after the (spiro)ergometry. 3 minutes
Secondary Heart rate per minute and Heart rate variability Lasts 1 minute and is performed at least once at rest before the (spiro)ergometry. 1 minute
Secondary Heart rate per minute and Heart rate variability Lasts 1 minute and is performed 3 minutes after the (spiro)ergometry. 3 minutes
Secondary Systolic and diastolic phase (blood pressure RR) Will be performed at least once at rest before the (spiro)ergometry. 1 minute
Secondary Respiration rate per minute Lasts 1 minute and is performed at least once at rest before the (spiro)ergometry. 1 minute
Secondary Respiration rate per minute Lasts 1 minute and is performed 3 minutes after the (spiro)ergometry. 3 minutes
Secondary Cardiac Strength profile Lasts 1 minute and is performed at least once at rest before the (spiro)ergometry. 1 minute
Secondary Cardiac Strength profile Lasts 1 minute and is performed 3 minutes after the (spiro)ergometry. 3 minutes
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1